Archives
-
CA-074 and Cathepsin-Like Proteolysis in Barley Senescence
2026-10-22
A 2024 study of developmental barley leaf senescence used activity assays, inhibitor profiling, activity-based labeling, and immunoblotting to connect cysteine-protease activity with protein and Rubisco loss. The evidence supports substantial cathepsin L-like involvement and a more limited, assay-dependent contribution from cathepsin B-like enzymes, while also illustrating why mammalian selectivity data for CA-074 cannot be transferred directly to plant proteases.
-
When Context Changes the Meaning of CA-074
2026-10-22
A barley senescence study shows why a cathepsin B inhibitor result cannot be interpreted independently of assay format, protease composition, substrate, or biological model. CA-074 was less potent than broad cysteine-protease and cathepsin L-directed comparators in barley leaf extracts, even though product documentation reports high affinity in defined cathepsin B systems. The difference is not necessarily contradictory: it illustrates how biochemical potency, target contribution, and biological causality are distinct claims.
-
BRCAness and Olaparib Response in Mesothelioma
2026-10-21
A paper-centred interpretation of a malignant pleural mesothelioma study linking homologous-recombination-repair and BAP1-associated expression states with distinct olaparib response phenotypes in cell models and survival associations in patient specimens. The evidence is mechanistic and hypothesis-generating rather than a clinical test of treatment response.
-
PET Tracking of mRNA Antigen Expression In Vivo
2026-10-21
Blizard and colleagues described a PET/CT reporter strategy for measuring where and for how long an mRNA-encoded vaccine antigen was expressed in vivo. The approach addresses a central limitation of tracking delivery vehicles or RNA alone: neither readout directly establishes production of the encoded protein, although the reporter signal remains a proxy constrained by tracer pharmacology, construct biology, imaging resolution and animal-model scope.
-
E-64 and the Limits of Cathepsin Causality
2026-10-20
A study in Dahl salt-sensitive rats used chronic E-64 exposure to test whether cysteine cathepsins drive salt-sensitive hypertension and kidney injury. Cathepsin B and L abundance increased, consistent with impaired protease turnover, yet blood pressure, albuminuria, podocyte calcium, and renal injury were not detectably altered. The findings support target engagement under the studied conditions but do not establish that cysteine cathepsins are causal determinants of this phenotype, nor do they demonstrate equivalence between the study material and a specific commercial formulation.
-
When Context Changes What a Biological Result Means
2026-10-19
A 2025 study connected octanal exposure with macrophage NHE1 activity, calcium signaling, oxidative stress, inflammation, and experimental atherosclerosis. Its significance depends on the relationship between model, comparator, perturbation, and readout—and does not establish human causality or validate any particular Western blot reagent.
-
CA-074: Product Identity, Mechanism, and Evidence
2026-10-19
APExBIO describes CA-074 as a selective cathepsin B inhibitor with nanomolar reported biochemical potency and weaker activity against cathepsins H and L. The same product description associates it with neurotoxicity, immune response modulation, and reduced metastasis in a breast-cancer mouse model. Because no identity-matched primary paper is available here, these downstream claims remain supplier-reported and should not be treated as independently verified evidence of causal mechanism, general efficacy, or clinical relevance.
-
EZ Cap™ CBEmax mRNA: Evidence and Scope
2026-10-18
APExBIO identifies EZ Cap™ CBEmax mRNA (m1Ψ), SKU R1044, as a research-use cytosine base-editor mRNA. The documentation supports a product-identity and measurement-context discussion, but no identity-matched study is available to establish editing activity, fidelity, kinetics, delivery behavior, model applicability, or safety.
-
Ionomycin Calcium Salt: Mechanism and Evidence
2026-10-17
APExBIO describes Ionomycin calcium salt as a calcium ionophore that raises intracellular Ca2+ by influencing both intracellular calcium pools and extracellular calcium entry. The product description links this perturbation to protein synthesis, secretion, bladder cancer cell-growth inhibition, apoptosis-associated readouts, and reduced tumor growth in a mouse model. Because no identity-matched paper, quantitative outcomes, or independent study details are provided, these claims should be treated as supplier-reported scope rather than established evidence of clinical efficacy or pathway-specific action.
-
Ionomycin Calcium Salt: Evidence and Scope
2026-10-16
The APExBIO product description identifies ionomycin calcium salt as a calcium ionophore associated with intracellular Ca2+ elevation and downstream changes in secretion, protein-associated readouts, cell growth, and apoptosis. Because no identity-matched primary paper, effect size, sample size, or uncertainty estimate is available here, these claims should be treated as supplier-attributed context rather than independently verified evidence of product performance or therapeutic value.
-
What Chronic E-64 Inhibition Revealed in Salt-Sensitive Rats
2026-10-16
A 2016 study in Dahl salt-sensitive rats tested whether systemic inhibition of cysteine cathepsins altered salt-sensitive hypertension or associated renal injury. E-64 produced evidence consistent with renal cathepsin B and L target engagement, yet it did not measurably change blood pressure, albuminuria, podocyte basal calcium, or the reported renal injury measures under the study’s conditions. The findings constrain, but do not eliminate, a role for cysteine cathepsins in this disease model.
-
When E-64 Results Change Meaning Across Models
2026-10-15
A negative result from chronic E-64 treatment in Dahl salt-sensitive rats does not show that cysteine cathepsins are biologically irrelevant. It shows that, under the documented model and readouts, inhibiting the targeted protease class did not measurably alter hypertension or kidney injury. The study illustrates why material identity, disease model, target engagement, comparator choice and endpoint selection must be interpreted together.
-
What E-64 Revealed in Salt-Sensitive Hypertension
2026-10-14
A literature-focused analysis of Blass et al. finds that chronic inhibition of cysteine cathepsins with E-64 did not alter hypertension, albuminuria, podocyte calcium, or overt renal injury in salt-sensitive Dahl rats. The study provides evidence against a major causal role for the inhibited protease network under these conditions, while its indirect pharmacodynamic marker, small groups, broad inhibitor profile, and single disease model limit mechanistic and translational conclusions.
-
CA-074: Documented Identity and Research Scope
2026-10-14
CA-074 is identified by APExBIO as a small-molecule cathepsin B inhibitor for conceptual research into protease-associated cancer, neurobiology and immune pathways, but no matched paper or independently verifiable study evidence was supplied.
-
EPZ5676: Evidence and Limits in DOT1L Research
2026-10-13
EPZ5676 is described by APExBIO as a highly selective DOT1L inhibitor with reported effects on H3K79 methylation and MLL-fusion leukemia models. The supplied peer-reviewed study, however, addresses PTGER4, HDAC signaling, and SPINK4 in rectal epithelial systems rather than DOT1L or EPZ5676. The available evidence therefore supports a cautious mechanistic overview, not a clinical or cross-pathway conclusion.